These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33084943)

  • 1. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).
    Kim Y; Vagia E; Viveiros P; Kang CY; Lee JY; Gim G; Cho S; Choi H; Kim L; Park I; Choi J; Chae YK
    Cancer Immunol Immunother; 2021 Apr; 70(4):961-965. PubMed ID: 33084943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
    Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
    J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

  • 9. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
    Zhang S; Liu J; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):623-628. PubMed ID: 28935016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
    Kubo T; Ninomiya T; Hotta K; Kozuki T; Toyooka S; Okada H; Fujiwara T; Udono H; Kiura K
    Clin Lung Cancer; 2018 Nov; 19(6):e861-e864. PubMed ID: 30172698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    Jin B; Chuang X; Liu Y
    J Thorac Oncol; 2018 Sep; 13(9):e174-e177. PubMed ID: 30166017
    [No Abstract]   [Full Text] [Related]  

  • 18. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.